DENOVO BIOPHARMA, LLC – Trademark Portfolio

Entity Type: 16

DENOVO BIOPHARMA, LLC holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 3 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include KINENZA. The owner is based in SAN DIEGO, CA.

6331 Nancy Ridge Drive

SAN DIEGO, CA 92121

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

DGM
DGM
Abandoned 2020
KINENZA
KINENZA
Registered 2014

Trademark Classifications

DENOVO BIOPHARMA, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (3 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does DENOVO BIOPHARMA, LLC have?

DENOVO BIOPHARMA, LLC has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 abandoned.

What trademark classes does DENOVO BIOPHARMA, LLC file in?

DENOVO BIOPHARMA, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are DENOVO BIOPHARMA, LLC's most well-known trademarks?

DENOVO BIOPHARMA, LLC's registered trademark portfolio includes well-known marks such as KINENZA. These are among 1 currently registered trademark in the portfolio.

What is DENOVO BIOPHARMA, LLC's trademark registration success rate?

DENOVO BIOPHARMA, LLC has a 33% trademark registration rate, with 1 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.